BlackRock ETF Trust. Holdings as of Jul 31, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| Merck & Co IncMRK | 5.91% | $659.33K | 5,064 |
| Gilead Sciences IncGILD | 4.86% | $542.32K | 4,165 |
| Johnson & JohnsonJNJ | 4.49% | $501.16K | 1,955 |
| Edwards Lifesciences CorpEW | 4.42% | $492.84K | 5,726 |
| Thermo Fisher Scientific IncTMO | 4.18% | $466.33K | 812 |
| Charles River Laboratories International IncCRL | 3.72% | $414.57K | 1,783 |
| BLACKROCK CASH FUNDS TREASURY SL AGENCY SHARESCash or money market | 3.68% | $410.00K | 410,000 |
| Danaher CorpDHR | 3.63% | $404.97K | 2,077 |
| Biogen IncBIIB | 3.52% | $392.71K | 1,935 |
| Waters CorpWAT | 3.50% | $390.52K | 1,035 |
| Mettler-Toledo International IncMTD | 3.48% | $388.07K | 274 |
| AbbVie IncABBV | 3.44% | $383.44K | 1,528 |
| Vertex Pharmaceuticals IncVRTX | 2.95% | $329.20K | 690 |
| Moderna IncMRNA | 2.92% | $326.07K | 5,948 |
| Novartis AG | 2.21% | $305.45K | 1,579 |
| Roche Holding AG | 2.12% | $291.95K | 540 |
| Dexcom IncDXCM | 2.61% | $291.49K | 3,493 |
| Amgen IncAMGN | 2.49% | $278.09K | 722 |
| Bio-Techne CorpTECH | 2.46% | $274.30K | 3,805 |
| Illumina IncILMN | 2.41% | $268.48K | 1,309 |
| Incyte CorpINCY | 2.12% | $236.77K | 1,981 |
| IQVIA Holdings IncIQV | 1.96% | $218.33K | 929 |
| Argenx SEARGX | 1.91% | $213.46K | 250 |
| BlackRock Funds IIICash or money market | 1.81% | $201.33K | 201,272 |
| Cytokinetics IncCYTK | 1.80% | $200.54K | 2,600 |
| Neurocrine Biosciences IncNBIX | 1.71% | $190.99K | 1,145 |
| Abbott LaboratoriesABT | 1.70% | $189.94K | 1,797 |
| Guardant Health IncGH | 1.53% | $170.09K | 1,050 |
| Roivant Sciences Ltd | 1.42% | $157.82K | 4,654 |
| AstraZeneca PLC | 1.33% | $148.44K | 875 |
| Bristol-Myers Squibb CoBMY | 1.27% | $141.66K | 2,169 |
| Axsome Therapeutics IncAXSM | 1.27% | $141.48K | 649 |
| BioMarin Pharmaceutical IncBMRN | 1.23% | $136.85K | 2,280 |
| Revolution Medicines IncRVMD | 1.22% | $135.58K | 723 |
| Bruker CorpBRKR | 1.04% | $115.88K | 1,844 |
| Protagonist Therapeutics IncPTGX | 0.96% | $106.58K | 780 |
| UCB SA | 0.77% | $98.57K | 333 |
| Alkermes PLC | 0.75% | $83.87K | 1,712 |
| Apogee Therapeutics Inc | 0.69% | $77.24K | 576 |
| Arcus Biosciences IncRCUS | 0.65% | $72.34K | 2,566 |
| Dianthus Therapeutics IncDNTH | 0.62% | $69.60K | 651 |
| MBX Biosciences IncMBX | 0.59% | $65.47K | 993 |
| BioNTech SEBNTX | 0.57% | $63.86K | 705 |
| Cogent Biosciences IncCOGT | 0.57% | $63.53K | 1,632 |
| Insmed IncINSM | 0.44% | $48.61K | 493 |
| Erasca IncERAS | 0.39% | $43.11K | 2,375 |
| Wuxi Biologics Cayman Inc | 1.17% | $16.68K | 26,500 |
| Avalo Therapeutics IncAVTX | 0.13% | $14.25K | 781 |
| Halozyme Therapeutics IncHALO | 0.11% | $12.79K | 155 |
| Sagimet Biosciences IncSGMT | 0.11% | $12.00K | 1,688 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.